Cost effectiveness of treatments for relapsed/refractory multiple myeloma: response to a methodology. RE: Hornberger J, Rickert J, Dhawan R, Liwing J, Aschan J, Löthgren M. The cost effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective. European Journal of Haematology 2010; 85 (6):484-491.

Autor:	Ishak J, Rodrigues F
Jazyk:	angličtina
Zdroj:	European journal of haematology [Eur J Haematol] 2011 Jul; Vol. 87 (1), pp. 95; author reply 96-7.
DOI:	10.1111/j.1600-0609.2011.01624.x
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu PDF